Meeting
2023 ASCO Annual Meeting
CRES3T: A single-arm confirmatory trial of S-1 plus cisplatin with concurrent radical-dose radiotherapy followed by surgery for superior sulcus tumor.
Authors
Kazuya Takamochi
Department of General Thoracic Surgery, Juntendo University School of Medicine, Tokyo, Japan
Kazuya Takamochi , Kenji Suzuki , Morihito Okada , Seiji Niho , Satoshi Ishikura , Shunsuke Oyamada , Takuhiro Yamaguchi , Hirotoshi Horio , Fumihiro Tanaka , Satoshi Shiono , Tomohiro Haruki , Norihito Okumura , Ichiro Yoshino , Hiroyuki Ito , Hidetaka Uramoto , Masahiro Tsuboi
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers
Track
Lung Cancer
Sub Track
Local-Regional Non–Small Cell Lung Cancer
Clinical Trial Registration Number
000014386
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 8514)
DOI
10.1200/JCO.2023.41.16_suppl.8514
Abstract #
8514
Poster Bd #
141
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Efficacy and safety of polymeric micelle paclitaxel (pm-Pac) plus tislelizumab and carboplatin for first-line treatment of patients with advanced squamous non-small-cell lung cancer.
First Author: Meiqi Shi
Poster
2022 ASCO Annual Meeting
Dose-finding and efficacy confirmation trial of the superselective intra-arterial infusion of cisplatin and concomitant radiotherapy for locally advanced maxillary sinus cancer (JCOG1212): Results of the efficacy confirmation phase in the T4a cohort.
First Author: Akihiro Homma
Poster
2024 ASCO Genitourinary Cancers Symposium
Updated results from AVENANCE: Real-world effectiveness of avelumab first-line maintenance (1LM) in patients (pts) with advanced urothelial carcinoma (aUC) and analysis of subsequent treatment.
First Author: Philippe Barthelemy
Poster
2024 ASCO Genitourinary Cancers Symposium
Pembrolizumab plus lenvatinib vs nivolumab plus cabozantinib in patients with metastatic renal cell carcinoma: A matching adjusted indirect comparison (MAIC).
First Author: Pratik Rane